跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
VEGZELMA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
VEGZELMA
Authorized
STANDARD
VEGZELMA
Celltrion Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
98891c6b6005edff
Company
Celltrion Inc
Type
Standard
Approval Details
Approval Id
98891c6b6005edff
Drug Approval Canada Name
VEGZELMA
Product Name
VEGZELMA
Status
Marketed
Status Date
2024-03-28
Original Market Date
2023-08-14
Din
02534177
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Schedule D , Prescription
Ahfs
10:00.00
Atc Original
L01FG01 BEVACIZUMAB
Atc Name
l 01 fg 01
Aig Number
0151381001
Company Name
Celltrion Inc
Company Address
23 Academy-Ro, Yeonsu-Gu, Incheon, --, Korea, Republic Of, 22014
Company Detail Path
/organization/celltrion-inc
Company Information
Pharmaceutical Company Name
Celltrion, Inc.
Name En
Celltrion, Inc.
Name Zh
塞尔群
Country Name
South Korea
Province Name
仁川广域市
City Name
Yeonsu-gu, Incheon
Address
Yeonsu-gu, Incheon, South Korea
Website
https://www.celltrion.com
Description
South Korean biopharmaceutical company headquartered in Incheon, developing and distributing biosimilar monoclonal antibody therapies for rheumatoid arthritis, cancer, and inflammatory diseases.
Active Ingredients
BEVACIZUMAB
100 MG / 4 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
98891c6b6005edff
Type
Standard
Back to Health Canada Approvals